Published in Medical Letter on the CDC and FDA, June 26th, 2005
The approval is based on results from one of the largest studies conducted to date of hospitalized patients with cSSSI. The study showed that MERREM, administered 500 mg IV every 8 hours, is a well-tolerated and effective treatment for patients with cSSSI, including the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.